TC
RCKT icon

TwinBeech Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

TwinBeech Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,649
Closed -$244K – 933
2025
Q1 		$244K Buy
+36,649
New +$362K ﹤0.01% 638
2024
Q2 		– Sell
-14,122
Closed -$380K – 750
2024
Q1 		$380K Buy
+14,122
New +$401K 0.01% 473

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

TwinBeech Capital's RCKT Position: Q2 2025 in Review

TwinBeech Capital sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 36,649 shares — an estimated $244K sold.

TwinBeech Capital first reported a position in RCKT in Q1 2024 and held it in 2 quarters. The position peaked at $380K in Q1 2024. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • TwinBeech Capital reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • TwinBeech Capital sold 36,649 Rocket Pharmaceuticals shares in Q2 2025, an estimated $244K.
  • TwinBeech Capital first reported a position in Rocket Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • TwinBeech Capital's Rocket Pharmaceuticals position peaked at $380K in Q1 2024.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on TwinBeech Capital's 13F filing for Q2 2025, filed 14 Aug 2025.